Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 10/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8225692 | 0.89 | DPP4 (0.59) | DPP4DPP7KCNH2ALDH1A1DPP8 | |
| Hydrochloric Acid SCHEMBL6149488 | 0.85 | DPP4 (0.43) | DPP4DPP7KCNH2ALDH1A1 | |
| SCHEMBL6207599 | 0.82 | DPP4 (0.48) | DPP4DPP7KCNH2ALDH1A1DPP8 | |
| SCHEMBL14655971 | 0.77 | DPP4 (0.45) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL14655365 | 0.77 | DPP4 (0.45) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL14656014 | 0.76 | DPP4 (0.73) | DPP4DPP7KCNH2 | |
| SCHEMBL3331895 | 0.75 | LMNA (0.59) | DPP4DPP7ALDH1A1 | |
| SCHEMBL5477707 | 0.75 | DPP4 (0.69) | DPP4DPP7KCNH2DPP8DPP9 | |
| SCHEMBL15203460 | 0.75 | DPP4 (0.69) | DPP4DPP7KCNH2DPP8DPP9 | |
| SCHEMBL1770232 | 0.74 | SLC1A2 (0.42) | DPP4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567489-B1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-20060166985-A1 | Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa | GLAXO GROUP LIMITED (GB) | 2006-07-27 | — | — | US | disclosed |
| EP-1567489-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004052851-A1 | PYRROLYDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA | GLAXO GROUP LIMITED (GB) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166985-A1 | Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa | TFPI, TFPI2, SERPINC1 | DPP4 383/4885DPP7 224/4885KCNH2 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.